Introduction
Chronic myeloid leukemia (CML) exemplifies importance of molecular pathways and their exact role in oncology. Imatinib mesylate first tyrosine kinase inhibitor (TKI) introduced into clinical practice has an ability to bind ATP-binding pockets of the ABL kinase domain (KD). This subsequently prevents the change in conformation of the protein to the active form of the molecule, leading to subsequent death of target cells. [1] These domains are amenable to mutations, and such mutations can lead to imatinib resistance. Multiple clinical trials such resistances have been frequently encountered (approximately 50-60%) [2] of patients. Clinical resistance is the hallmark for checking any underlying mutations. This fact is enough to speculate that such mutant clones might be present even before the start of therapy and might be pre-existing. [3] Imatinib selects sensitive clones, and thus, resistant clones are spared, leading to the early clinical resistance to standard therapy. Patients with CML can acquire more than one BCR-ABL-1 mutation, Genomic DNA was extracted from peripheral blood mononuclear cells using QIAamp DNA Mini Kit (Qiagen, according to the manufacturer's recommendations). Quantity was estimated using Qubit fluorometer version 2.1. Mutated or wild-type sequences were specifically amplified in a separate PCR reaction performed on DNA in 25 µL reaction mixture using PCR master mix (Fermentas, Thermo Scientific, according to manufacture instruction). Healthy volunteer was used as negative control.
Following PCR cycle was designed using allele-specific and reverse primers: For the Thr315Ile mutation, F315C Table 1 , of the 50 patients of imatinib-resistant cases, 33 were males and 17 were females. Average age of the study group was 40.75 years. Of the 50 selected, 47(94%) were in chronic phase, whereas 2 (4%) were in accelerated phase, 1 (2%) was in blastic crisis. 29 of 50 were having low EUTOS score, whereas SOKAL score was low in 20, intermediate in 21, while only 9 were having high SOKAL at presentation.
Results

As per
We treated every patient with imatinib 400 mg per day, and dose was escalated to 600 mg at the time of clinical evidence of imatinib resistance, 28% (14/50) of the patients did not achieve complete hematological response at the end of 3 months of standard dose of imatinib (i.e., 400 mg per day). 86% (43/50) of the study group patients failed to achieve complete cytogenetic response (CCyR) at the end of 1 year of imatinib-standard dose. Only 8% (4/50) of the patients in this study group achieved major molecular response (MMR) at the end of 18 months of standard-dose imatinib.
Cumulative imatinib dose was <400 mg per day in 11 (22%) patients, >600 mg per day in 1 patient, whereas it was 400-600 mg in 38 (76%) of the cases. 88% (n = 44) were having drug to drug compliance >85%.
Of the study population, 96% (43/50) showed either one or more than 1 mutation. T315I mutation was detected in 5 (10%) patients. 1 was having isolated T3151. M351T mutation was seen in 32 (64%) patients. Of which 32% (16/50) were having isolated M351T mutation.
Median duration of imatinib resistance and mutation detection was 36 months. Median duration of imatinib treatment in these patients before the detection of mutation was 48 months. Three patients stopped imatinib, because of pregnancy, and 1 patient was intolerant to imatinib. As per Table 2 , response to 600 mg of imatinib in T315I mutation, none achieved CCyR (n = 5) and 2 lost the hematological response also. In isolated M315T mutation (n = 16), 4 (25%) of the patient achieved CCyR and 1 achieved CCyR after 1 year. About the molecular response, only 3 (18%) achieved it and 2 lost the MMR within 12 months. 1 lost MMR after 12 months of imatinib 600 mg.
Discussion
High incidence (32%) of M351T was detected in our study, as compared to data by another Indian study by Shrivastava and Dutt, they reported an incidence of M351T of 10% in their study. [6] They studied imatinib resistance in chronic phase only and not in accelerated phase and blastic Crisis. Second, the method they used was bidirectional sequencing analysis of the amplicon, acquired from RNA of the sample containing adequate BCR-ABL was compared to human genome sequencing [ Table 3 ]. However, sensitivity and reliability of mutation detection are critically dependent on the method employed, awe used ASO-PCR while they used bidirectional sequencing as the method of detection of mutation. Direct sequencing is not specifically designed to detect the mutation concerned. [5] ASO-PCR is proved to be a very economical, sensitive, and rapid technique for the detection of KD mutations M351T, F317L, and F311C ABL mutation and is more sensitive than mutation detection by sequencing. [5] In a study done at AIIMS by Mir et al., 100 CML patients were screened for M351T mutation after 3 years of imatinib initiation. (40%) 40/100 were positive for M351T, [5] which is comparable to ours. We encountered a very high level of mutations compared to small sample size, and it may be because our patients progressed well within natural history of CML. This fact is reflected by median months on imatinib, i.e., 48 (4 years). BCR-ABL KD mutations account for 50-90% of the imatinib resistance observed in patients of CML-CP. [7, 8] In the preimatinib era, CML-CP used to be around 4-6 years, accelerated phase for 18 months, and blastic phase for 6 months.
10% of mutations detected are M351T, in the western world. M351T has a low-level imatinib sensitivity. It is thought to be associated with a loss of function and may be selected on drug exposure. [1] M351T mutation reduces BCR-ABL kinase activity and transforming capacity. [9] Various studies showed that at higher concentrations of imatinib, different KD, and mutations retain sensitivities. [10] Thus, high doses of imatinib may render resistant clones as sensitive. However, what is the dose of imatinib required to achieve this? in the study done by Branford et al., they found that 600 mg imatinib was not sufficient to be clinically beneficial. [11] Same is what we studied in our data, 600 mg imatinib was not sufficient as far as M351T mutations are concerned. Table 2 , response to 600 mg imatinib, in isolated M315T mutation (n = 16), 4 (25%) of the patient achieved CCyR, 1 achieved CCyR after 1 year. About the molecular response only 3 (18%) achieved it, 2 lost the MMR within 12 months. 1 lost MMR after 12 months of imatinib 600 mg. As compared to the 74 patients data quoted by Breccia et al. regarding response to high-dose imatinib, CCyR was achieved in 37% patients. [12] The reason for the low response in our study was low dose of imatinib offered for a relatively prolonged period of time. 400 mg of imatinib was given for a median duration of 48 months. The other reason was possible emergence of clonal evolution which was not done in our study. Third, compliance was <85% in 12% of the cases, leading to low imatinib trough level might be the other reason for low response to high dose of imatinib in our patient. Thirdly selection bias also can be the other reason, as we retrospectively selected the resistant patient and retrospectively analyzed the response to both the standard dose as well as 600 mg dose of imatinib. Further analysis, in accordance to Marin et al., [13] we found the response to 600 mg of imatinib was not durable. All of the 32 patients with M351T mutation treated with 600 mg Imatinib progressed within median of 21 months (range 8-30 months) of therapy, lading to escalation of imatinib.
As per
M351I can be detected using more sensitive ASO-PCR method. M351T mutation precedes the emergence of T315I. If we detect M351I earlier, we may prevent the emergence of T315I.
